Abivax SA (ABVX) Stock Statistics & Valuation Metrics

Abivax SA has a market cap or net worth of €7.41B. The enterprise value is €7.59B.

Abivax SA has 79,167,435 shares outstanding. The number of shares has decreased by -2.65% in one year.

Abivax SA’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -47.96%.

The current PE Ratio of Abivax SA is ―. Abivax SA’s PEG ratio is -0.34.

In the last 12 months, Abivax SA had revenue of 0.00 and earned -336.10M in profits. Earnings per share was -4.83.

In the last 12 months, operating cash flow was -162.09M and capital expenditures -142.00K, giving a free cash flow of -162.23M billion.

Abivax SA pays an annual dividend of ―, resulting in a dividend yield of ―

Abivax SA upcoming earnings date is Jun 8, 2026, Before Open (Confirmed).

Abivax SA as a current ratio of 8.75, with Debt / Equity ratio of 7.05%

In the past 12 months, Abivax SA has paid 2.79M in taxes.

Abivax SA EV to EBITDA ratio is -31.60, with an EV/FCF ratio of -48.61.

Abivax SA has €530.38M in cash and marketable securities with €32.09M in debt, giving a net cash position of €498.29M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Abivax SA is €130.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy